Quality of life of postmenopausal women in the ATAC ("Arimidex", tamoxifen, alone or in combination) trial after completion of 5 years' adjuvant treatment for early breast cancer.
about
Natural products as aromatase inhibitorsEffects of ospemifene on the female reproductive and urinary tracts: translation from preclinical models into clinical evidenceVulvovaginal atrophy.Urban-Rural Variations in Quality-of-Life in Breast Cancer Survivors Prescribed Endocrine Therapy.American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer.Amelioration of sexual adverse effects in the early breast cancer patientQuality of life among a population-based cohort of older patients with breast cancer.Quality of life of breast cancer patients medicated with anti-estrogens, 2 years after acupuncture treatment: a qualitative studyCytochrome P450 2D6 activity predicts discontinuation of tamoxifen therapy in breast cancer patientsPhase III comparison of tamoxifen versus tamoxifen plus ovarian function suppression in premenopausal women with node-negative, hormone receptor-positive breast cancer (E-3193, INT-0142): a trial of the Eastern Cooperative Oncology Group.Health-related quality of life in breast cancer patients: a bibliographic review of the literature from 1974 to 2007.Optimizing expectations to prevent side effects and enhance quality of life in breast cancer patients undergoing endocrine therapy: study protocol of a randomized controlled trialFatigue in patients with advanced renal cell carcinoma receiving sunitinib on an intermittent versus continuous dosing schedule in a randomized phase II trial.Health-related quality of life and cancer clinical trials.Sexual problems during the first 2 years of adjuvant treatment with aromatase inhibitors.If I am in the mood, I enjoy it: an exploration of cancer-related fatigue and sexual functioning in women with breast cancer.Long-term assessment of quality of life in the Intergroup Exemestane Study: 5 years post-randomisation.Perspectives of postmenopausal breast cancer survivors on adjuvant endocrine therapy-related symptoms.Validity and reliability of the Patient-Reported Arthralgia Inventory: validation of a newly-developed survey instrument to measure arthralgia.Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase 3 randomised trials.Effects of vaginal estrogens on serum estradiol levels in postmenopausal breast cancer survivors and women at risk of breast cancer taking an aromatase inhibitor or a selective estrogen receptor modulator.Role of aromatase inhibitors in the upfront adjuvant hormonal therapy of postmenopausal patients with breast cancerCost-effectiveness analysis of anastrozole vs tamoxifen in adjuvant therapy for early stage breast cancer in the United Kingdom: the 5-year completed treatment analysis of the ATAC ('Arimidex', Tamoxifen alone or in combination) trial.Anastrozole-associated joint pain and other symptoms in patients with breast cancer.Lichen sclerosus in a breast cancer survivor on an aromatase inhibitor: a case report.Patient-reported outcomes with anastrozole versus tamoxifen for postmenopausal patients with ductal carcinoma in situ treated with lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trialHealth-related quality of life of postmenopausal Chinese women with hormone receptor-positive early breast cancer during treatment with adjuvant aromatase inhibitors: a prospective, multicenter, non-interventional study.Long-term safety of aromatase inhibitors in the treatment of breast cancer.Patient-Reported Outcomes and Early Discontinuation in Aromatase Inhibitor-Treated Postmenopausal Women With Early Stage Breast Cancer.Time course of arthralgia among women initiating aromatase inhibitor therapy and a postmenopausal comparison group in a prospective cohort.Quality of life assessment in women with breast cancer: a prospective study including hormonal therapy.Quality of life and adjuvant systemic therapy for early-stage breast cancer.Breast cancer in young women and its impact on reproductive functionReview of the ATAC study: tamoxifen versus anastrozole in early-stage breast cancer.Long-term efficacy and safety of letrozole for the adjuvant treatment of early breast cancer in postmenopausal women: a reviewAromatase inhibitors in the treatment of breast cancer in post-menopausal female patients: an update.Anastrozole Use in Early Stage Breast Cancer of Post-Menopausal Women.Update on the use of aromatase inhibitors in early-stage breast cancer.Comparative review of anastrozole, letrozole and exemestane in the management of early breast cancer.The potential adverse effects of aromatase inhibitors on wound healing: in vitro and in vivo evidence.
P2860
Q24620153-B4F9E9ED-EF23-457C-B6E2-8CF7662D4F0FQ30380010-AD010975-AF3F-4A3F-B656-759E8C229ACEQ33566744-97BE4F6F-F27F-4B6C-BCA1-77DD130A0867Q33616178-9AFEABD5-A496-4BA4-8564-6633C2C2897EQ33631047-F5487B6E-F572-43D1-8422-4063025B60EDQ34065198-4B16B892-EBB1-4433-90DB-0D0A7B41712EQ34287873-2153B9DF-0547-44EA-BF72-43B83BE33F55Q34345677-98FE57CA-B84C-4001-BF08-0AC71894BBF6Q34346501-7C5A3136-3C22-492B-89D6-3D1428F23FBAQ34611626-DDBDC629-B202-433C-B24F-B1C312DB2F93Q34818002-3999FA8A-64FE-42DE-8A01-374CD09761D0Q34991931-F3559855-2336-42C4-944C-D269B74D887FQ34998569-99EF466F-88AF-4123-A3C3-003FDB6FC1EEQ35076356-8543034E-1B27-4BE3-BF33-672304E5534DQ35207952-0654F9A4-0C39-4688-8CE6-4C4D3684CB76Q35584799-D532A245-54DE-4D6B-AB57-C6EEAFED284DQ35832316-BE00C258-0DFB-44D2-94E0-7AE6DAD0B30DQ35845258-79B858C6-0C29-4785-AC3F-8D5B5BE92556Q35914925-CAECD2FD-DA14-4C28-91F9-0054421E1039Q36036025-60EC5602-E64E-4359-A363-B8BA8E916391Q36095148-6EB29AF0-3B71-48D2-B747-47F367E85A52Q36169971-CAC38BB9-A26B-410C-B87E-91CCB55067A0Q36610798-E24D4F70-FC79-43E4-9881-B9FC7A78A77EQ36655900-AEED5F85-C152-4720-8EB7-09AEF8608CD5Q36688701-17CFB395-1E36-4010-8EDF-183E74958F58Q36689309-B7FC79B8-7E25-44E6-B964-3F33FE5B508EQ36725225-6036A0A5-5C92-49D6-A92E-96A507BCD842Q36822883-34FCDF9D-E35D-4D92-95B2-3F98E4A5F1FEQ36884366-C2110526-34E3-4E04-AD23-72A654F76611Q36941450-D132112C-74F8-45AE-A37A-9DD3231C5D3BQ36998149-A4E91A84-8856-4743-BABE-493BDEFE9E38Q37008863-36494212-776A-4A22-A8B7-2689856DC0B4Q37153908-9D5CE580-35A9-44DA-B39D-5F266E2173D0Q37338231-5D0043CE-7AB3-4587-AF48-30C5A289354BQ37354647-5B6DAD28-403B-46BD-987C-1413CCB9936AQ37355574-1BE10ADA-42DA-4553-90CD-9D8F6BE433FCQ37366511-747CE41E-D2DD-4549-8AC8-AE4BEEEE8EB4Q37467243-77A77CDE-D1F4-4757-AB8B-53DB56EE45B7Q37483932-61089F7C-421B-46D9-B5F5-45F5718913C0Q37567851-FDD58BDF-1553-48D6-B632-477FFBFEF5DE
P2860
Quality of life of postmenopausal women in the ATAC ("Arimidex", tamoxifen, alone or in combination) trial after completion of 5 years' adjuvant treatment for early breast cancer.
description
2006 nî lūn-bûn
@nan
2006 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
name
Quality of life of postmenopau ...... tment for early breast cancer.
@ast
Quality of life of postmenopau ...... tment for early breast cancer.
@en
Quality of life of postmenopau ...... tment for early breast cancer.
@nl
type
label
Quality of life of postmenopau ...... tment for early breast cancer.
@ast
Quality of life of postmenopau ...... tment for early breast cancer.
@en
Quality of life of postmenopau ...... tment for early breast cancer.
@nl
prefLabel
Quality of life of postmenopau ...... tment for early breast cancer.
@ast
Quality of life of postmenopau ...... tment for early breast cancer.
@en
Quality of life of postmenopau ...... tment for early breast cancer.
@nl
P2093
P50
P1476
Quality of life of postmenopau ...... tment for early breast cancer.
@en
P2093
ATAC Trialistsa9 Group
David Cella
Gershon Locker
Jack Cuzick
Peter Barker
P2888
P304
P356
10.1007/S10549-006-9260-6
P407
P577
2006-06-21T00:00:00Z
P6179
1007691459